BR112018074472A2 - interfaces proteicas - Google Patents

interfaces proteicas

Info

Publication number
BR112018074472A2
BR112018074472A2 BR112018074472-7A BR112018074472A BR112018074472A2 BR 112018074472 A2 BR112018074472 A2 BR 112018074472A2 BR 112018074472 A BR112018074472 A BR 112018074472A BR 112018074472 A2 BR112018074472 A2 BR 112018074472A2
Authority
BR
Brazil
Prior art keywords
compounds
targeted
dna damage
damage repair
cancer cells
Prior art date
Application number
BR112018074472-7A
Other languages
English (en)
Inventor
Charly CHAHWAN
Maria SOLOVEYCHIK
Original Assignee
Synthex, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthex, Inc. filed Critical Synthex, Inc.
Publication of BR112018074472A2 publication Critical patent/BR112018074472A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/85—Saccharomyces
    • C12R2001/865—Saccharomyces cerevisiae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)

Abstract

o presente relatório provê métodos para tratar condições, incluindo câncer, utilizando compostos que podem ser direcionados para células cancerígenas resistentes. os compostos podem ser utilizados para sensibilizar células cancerígenas resistentes ou reduzir a proliferação de células. os compostos podem ser direcionados para proteínas na rota de reparo de dano em dna levando a uma redução do reparo de dano em dna nas células alvo.
BR112018074472-7A 2016-05-27 2017-05-26 interfaces proteicas BR112018074472A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662342840P 2016-05-27 2016-05-27
US62/342,840 2016-05-27
US201662384226P 2016-09-07 2016-09-07
US62/384,226 2016-09-07
PCT/US2017/034870 WO2017205852A2 (en) 2016-05-27 2017-05-26 Protein interfaces

Publications (1)

Publication Number Publication Date
BR112018074472A2 true BR112018074472A2 (pt) 2019-03-19

Family

ID=60411842

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018074472-7A BR112018074472A2 (pt) 2016-05-27 2017-05-26 interfaces proteicas

Country Status (9)

Country Link
US (3) US10188691B2 (pt)
EP (2) EP4269427A3 (pt)
JP (3) JP7080878B2 (pt)
CN (2) CN109562138B (pt)
AU (4) AU2017271678B2 (pt)
BR (1) BR112018074472A2 (pt)
CA (1) CA3025423A1 (pt)
MX (2) MX2018014366A (pt)
WO (1) WO2017205852A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7080878B2 (ja) 2016-05-27 2022-06-06 シンセックス， インコーポレイテッド タンパク質界面
WO2019099678A1 (en) 2017-11-16 2019-05-23 Synthex, Inc. Selective modulation of protein-protein interactions
WO2019104244A1 (en) 2017-11-22 2019-05-31 Synthex, Inc. Peptides for inhibiting rad51
BR112021021839A2 (pt) * 2019-05-01 2022-01-04 Innate Biologics Llc Composições imunomodulatórias e métodos
JP2022532216A (ja) 2019-05-15 2022-07-13 シンセックス， インコーポレイテッド タンパク質の選択的分解
JP2023145812A (ja) * 2020-08-17 2023-10-12 国立大学法人東海国立大学機構 人工タンパク質、Ｒａｓ阻害剤及び抗がん剤

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
US5733726A (en) * 1995-06-07 1998-03-31 Emory University Cytotoxicity-based genetic selection system (TOXSEL)
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
WO1998007845A1 (en) 1996-08-23 1998-02-26 President And Fellows Of Harvard College Interaction trap assay, reagents and uses thereof
US6037125A (en) * 1996-11-05 2000-03-14 Lexicon Genetics Incorporated Disruption of the mammalian RAD51 protein and disruption of proteins that associate with mammalian RAD51 for hindering cell proliferation and/or viability of proliferating cells
CA2417135C (en) 1997-11-19 2005-04-12 Microbia, Inc. Chimeric pre-activated transcription factors
US6500636B1 (en) 1997-11-19 2002-12-31 Microbia, Inc. Chimeric pre-activated transcription factors
US6303302B1 (en) 1997-11-19 2001-10-16 The Whitehead Institute For Biomedical Research Regulation of fungal gene expression
WO1999035282A1 (en) * 1998-01-09 1999-07-15 Tvw Telethon Institute For Child Health Research Peptide detection method
AU775227B2 (en) 1998-03-26 2004-07-22 Glaxo Group Limited Assay methods
US6332897B1 (en) 1998-03-27 2001-12-25 Glaxo Wellcome Inc. Assay methods
US6316223B1 (en) 1998-03-30 2001-11-13 Rigel Pharmaceuticals, Inc. Mammalian protein interaction cloning system
US6114111A (en) 1998-03-30 2000-09-05 Rigel Pharmaceuticals, Inc. Mammalian protein interaction cloning system
DE19901008A1 (de) * 1999-01-13 2000-07-20 Deutsches Krebsforsch Peptide zur Inhibierung von HPV E6-Proteinen
AU3733100A (en) 1999-03-09 2000-09-28 Lexicon Genetics Incorporated Compounds that disrupt mammalian rad51 activity
US7270969B2 (en) * 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
AU783233B2 (en) 1999-06-07 2005-10-06 Tet Systems Holding Gmbh & Co. Kg Novel TET repressor-based transcriptional regulatory proteins
US6790607B1 (en) 1999-10-07 2004-09-14 Hybrigen, Inc. Adjustable sensitivity, genetic molecular interaction systems, including protein-protein interaction systems for detection and analysis
IL148967A0 (en) 1999-10-07 2002-11-10 Hybrigen Inc Adjustable sensitivity, genetic molecular interaction systems, including protein-protein interaction systems for detection and analysis
US20020086840A1 (en) 2000-01-26 2002-07-04 Zarling David A. Use of Rad51 inhibitors for p53 gene therapy
US7378248B2 (en) 2000-03-06 2008-05-27 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein-protein interaction
US7566765B2 (en) 2000-03-06 2009-07-28 Rigel Pharmaceuticals, Inc. Heterocyclic compounds containing a nine-membered carbon-nitrogen ring
US7105341B2 (en) 2000-03-06 2006-09-12 Rigel Pharmaceuticals. Inc. In vivo production of cyclic peptides
US7252952B2 (en) 2000-03-06 2007-08-07 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein—protein interaction
AU2001245584B2 (en) 2000-03-08 2007-02-08 Phylogica Limited Improved reverse n-hybrid screening method
US20030211495A1 (en) 2000-03-08 2003-11-13 Richard Hopkins Reverse n-hybrid screening method
WO2001066787A1 (en) 2000-03-08 2001-09-13 Tvw Telethon Institute For Child Health Research Improved reverse n-hybrid screening method
GB0006572D0 (en) 2000-03-17 2000-05-10 Isis Innovation Novel transcription transactivator protein
WO2003013488A2 (en) 2001-08-09 2003-02-20 Pangene Corporation Methods and compositions for inhibiting rad51
US20030229004A1 (en) 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
WO2004042064A2 (en) * 2002-11-07 2004-05-21 Imperial College Innovations Limited Disorders of lipid metabolism
JP2004215624A (ja) * 2003-01-17 2004-08-05 Celestar Lexico-Sciences Inc 相互作用インヒビターの検出方法、相互作用インヒビターライブラリーおよびインヒビター検出キット
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
JP2005095613A (ja) 2003-09-04 2005-04-14 Taiyo Parts Kk 昇降装置
CN1905864B (zh) * 2003-12-01 2011-04-06 库多斯药物有限公司 用于治疗癌症的dna损伤修复抑制剂
EP1731609A4 (en) 2004-03-30 2010-04-07 Genomidea Inc INHIBITOR OF THE EXPRESSION OF RAD51, MEDICAMENT CONTAINING THE INHIBITOR AS ACTIVE INGREDIENT AND USE THEREOF
US20060116316A1 (en) 2004-10-14 2006-06-01 Kinsella Todd M Heterocyclic inhibitors of IRES-mediated translation and methods of use thereof
RU2446796C2 (ru) 2006-12-26 2012-04-10 Фармасайкликс, Инк. Способ использования ингибиторов гистондеацетилазы и мониторинга биомаркеров в комбинированной терапии
US8759089B2 (en) 2007-02-06 2014-06-24 Geneprotech, Inc. Methods and systems for high homologous recombination (“HR”) targeting efficiency
US7892823B2 (en) 2007-02-06 2011-02-22 Geneprotech, Inc. Methods and systems for high homologous recombination (“HR”) targeting efficiency
US8105493B2 (en) 2007-06-29 2012-01-31 Jnc Corporation Aggregation and dispersion methods of magnetic particles, separation and detection methods using the same and detection kit
US8597949B2 (en) 2007-07-28 2013-12-03 The University Of Chicago Methods and compositions for modulating RAD51 and homologous recombination
US9518097B2 (en) 2007-11-09 2016-12-13 Board Of Trustees Of Michigan State University Identification and use of genes encoding amatoxin and phallotoxin
US9273100B2 (en) 2007-11-09 2016-03-01 Board Of Trustees Of Michigan State University Use of Galerina marginata genes and proteins for peptide production
US9150897B2 (en) 2010-08-06 2015-10-06 The Regents Of The University Of California Expression and purification of fusion protein with multiple MBP tags
US9249410B2 (en) 2010-12-15 2016-02-02 The Johns Hopkins University Two-hybrid based screen to identify disruptive residues at multiple protein interfaces
WO2014085545A1 (en) 2012-11-30 2014-06-05 The University Of Chicago Methods and compositions involving rad51 inhibitors
US20170014360A1 (en) 2014-03-10 2017-01-19 The University Of Chicago Methods of treating cancer using rad51 small molecule stimulators
US10421753B2 (en) 2015-03-02 2019-09-24 The Regents Of The University Of California RAD51 inhibitors and uses thereof
JP7080878B2 (ja) 2016-05-27 2022-06-06 シンセックス， インコーポレイテッド タンパク質界面

Also Published As

Publication number Publication date
AU2021205010A1 (en) 2021-08-05
CA3025423A1 (en) 2017-11-30
JP2022119883A (ja) 2022-08-17
US20190216879A1 (en) 2019-07-18
EP3463414A4 (en) 2019-10-23
AU2017271678A1 (en) 2018-12-13
US20170368132A1 (en) 2017-12-28
CN116217657A (zh) 2023-06-06
WO2017205852A3 (en) 2018-01-25
JP7479421B2 (ja) 2024-05-08
MX2023002591A (es) 2024-02-08
AU2017271678B2 (en) 2021-05-06
AU2021205010B2 (en) 2022-08-11
EP4269427A3 (en) 2023-11-22
JP2019527066A (ja) 2019-09-26
JP2024099695A (ja) 2024-07-25
EP3463414C0 (en) 2023-09-13
CN109562138A (zh) 2019-04-02
EP4269427A2 (en) 2023-11-01
AU2022259709A1 (en) 2022-11-24
US20210252100A1 (en) 2021-08-19
US10188691B2 (en) 2019-01-29
JP7080878B2 (ja) 2022-06-06
AU2024204362A1 (en) 2024-07-11
MX2018014366A (es) 2019-04-11
EP3463414B1 (en) 2023-09-13
EP3463414A2 (en) 2019-04-10
CN109562138B (zh) 2023-03-21
WO2017205852A2 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
BR112018074472A2 (pt) interfaces proteicas
BR112019000327A8 (pt) Anticorpo para anticlaudina 18a2 e uso do mesmo
BR112016015677A2 (pt) Moléculas de anticorpo isoladas capazes de se ligarem à pd-1 humana, bem como seu método de produção e seu uso, composições farmacêuticas, ácido nucleico, vetor de expressão, célula hospedeira, e método para detecção de pd-1 em uma amostra biológica
BR112018002274A2 (pt) anticorpos anti-pd-1
BR112018000768A2 (pt) anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
BR112018005164A2 (pt) anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de um indivíduo que tem câncer
BR112016014293A2 (pt) região de fragmento cristalizável canino, anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, e, método para aumentar a atividade de uma célula imune
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
BR112018002824A2 (pt) anticorpo, polinucleotídeo, vetor, célula, métodos para expressar o anticorpo, para tratar uma condição associada com pd-1 e para tratar uma condição em um sujeito, kit, composição farmacêutica e uso do anticorpo
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
BR112017007379A2 (pt) moléculas de anticorpo para pd-l1 e usos das mesmas
BR112015022852A2 (pt) mecanismos de processamento de vetor que tem configurações de percurso de dados programáveis para proporcionar processamento de vetor de múltiplos modos, e processadores de vetor, sistemas, e métodos, relacionados
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
BR112016004020A2 (pt) introgressão de alelo não meiótico eficiente
BR112018013653A2 (pt) anticorpos anti-pd-1
BR112015031639A2 (pt) integração alvo
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
BR112017020002A2 (pt) Combinação de inibidor de hdac e anticorpo anti- pd-1 para o tratamento de câncer
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
BR112017013956A8 (pt) proteínas de fusão de citocinas
BR112018067951A2 (pt) moléculas que se ligam a ilt7 e métodos de uso destas
BR112016026136A2 (pt) composições e métodos para aumentar o desenvolvimento e o rendimento vegetal
BR112016004324A2 (pt) anticorpos
BR112017023131A2 (pt) anticorpos anti- fcrn

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]